



IL "SAN MATTEO COMPLEXITY STUDY" (SMAC STUDY)

Gino Roberto Corazza
Marco V. Lenti
Alice S. Brera
Catherine Klersy
Antonio Di Sabatino

I Clinica Medica, Biostatistics and CT Centre
Fondazione IRCCS Policlinico San Matteo
Università di Pavia

AN INTRODUCTORY & SUBTLE TERMINOLOGICAL DIFFERENCE

Complexity, a new paradigm of clinical medicine

Complicated



complicatūm



**compiegato,
arrotolato
difficile da capire**

Complex



complexūs



**abbracciato,
intrecciato
interconnesso**

BRINGING COMPLEXITY INTO CLINICAL PRACTICE

- in the last decades, ageing of the general population has favoured the occurrence of chronic diseases, which tend to accumulate over the time, generating multimorbidity
- multimorbidity has been considered for years the hallmark of CC, but recent studies have shown that CC is something more and different
- CC originates from the interaction between patient's own factors and other external, contextual factors → a *complex system* is a cluster of individual factors from whose dynamic interaction new properties of the system itself emerge
- as a consequence, the observable outcomes of a CS are more than the sum of its single parts
- CC is one of the most challenging issue of modern medicine, since current health systems are still focused on single diseases or organ pathologies

COMPLEXITY IS A CHALLENGING ISSUE

J Whittle & H Bosworth

Studying complexity is complex

J Gen Intern Med 2007

BJ Turner & L Cuttler

The complexity of measuring clinical complexity

Ann Intern Med 2011

MM Safford


The complexity of complex patients

J Gen Intern Med 2015


THE INTRICATE FEATURES OF CSs

- ***co-evolution:*** as CSs are embedded within other systems, the evolution of one system influences and is influenced by that of other systems
- ***adaptivity:*** as individual components can change, a CS can adapt its behaviour over time
- ***non-linearity:*** small changes in a single part of the CS may lead to huge changes in global outcomes
- ***unpredictability:*** CSs are not governed by a simple cause/effect model

THE ZONE OF COMPLEXITY





CSs HAVE NON-LINEAR AND UNPREDICTABLE BEHAVIOUR




CAPACITY TO COPE WITH COMPLEXITY CANNOT BE INFERRED FROM TEXTBOOKS

**reductionist
mindset**





**complexity
mindset**

THE CONCENTRIC COMPONENTS OF CC



TREATMENT BASED ON CPG FOR A HYPOTHETICAL 80yr-OLD WOMAN WITH MULTIMORBIDITY



Time

MEDICATIONS

Time

MEDICATIONS

7:00 am

Ipratropium md inhaler
Alendronate 70 mg/wk

1:00 pm

Ipratropium md inhaler
Calcium 500 mg
Vitamin D 200 IU

8:00 am

Calcium 500 mg
Vitamin D 200 IU
Hydrochlorothiazide 12,5 mg
Lisinopril 40 mg
Glyburide 10 mg
Aspirin 81 mg
Metformin 850 mg
Naproxen 250 mg
Omeprazole 20 mg

7:00 pm

Ipratropium md inhaler
Metformin 850 mg
Calcium 500 mg
Vitamin D 200 IU
Lovastatin 40 mg
Naproxen 250 mg

11:00 pm


Ipratropium md inhaler

20 doses, 12 separate medications, 5 times/day

THE "SMAC" STUDY

- *1451 consecutive pts* enrolled over a 2-yr period (Nov 2017 – Nov 2019)
- *power of the study* 1000 pts will allow to show an increase in R from 0.80 to 0.84 with power 90% & alpha 1% 2-sided for the correlation of the complexity index and length of stay
- *primary end-point* length of stay of the index hospitalisation
- *secondary end-points* hospital readmission within 1 mo, # of readmission in the first yr, # of ER accesses in the first yr, # of drugs prescribed in the first yr, mortality at 1 and 5 yrs, hospital reimbursement according to the regional DRG system
- *follow-up* at mo 4-8-12, then at yrs 2-3-4-5
- *source* for a number of sub-projects


THE VECTOR MODEL OF PATIENT COMPLEXITY



CC DOMAINS & RELATED VARIABLES. RESULTS OF A CONSENSUS MEETING

BIOLOGICAL DOMAIN		
Age > 75 years	yes <input type="checkbox"/>	no <input type="checkbox"/>
Intake ≥ 5 medications	yes <input type="checkbox"/>	no <input type="checkbox"/>
CIRS > 3 and/or CIRS severity >3	yes <input type="checkbox"/>	no <input type="checkbox"/>
↑ frailty (Edmonton Frail Scale > 5)	yes <input type="checkbox"/>	no <input type="checkbox"/>
↓ mobilization (Barthel < 60)	yes <input type="checkbox"/>	no <input type="checkbox"/>
SOCIO-ECONOMIC DOMAIN		
Living alone	yes <input type="checkbox"/>	no <input type="checkbox"/>
Income < 1000 €/month	yes <input type="checkbox"/>	no <input type="checkbox"/>
Unemployment/precarious work	yes <input type="checkbox"/>	no <input type="checkbox"/>
Dependent/disabled family member	yes <input type="checkbox"/>	no <input type="checkbox"/>
Need for a caregiver	yes <input type="checkbox"/>	no <input type="checkbox"/>
BEHAVIORAL DOMAIN		
Inadequate adherence to medications	yes <input type="checkbox"/>	no <input type="checkbox"/>
Active smoking of at least 4 cigarettes/day	yes <input type="checkbox"/>	no <input type="checkbox"/>
Alcohol (>3 Alcohol Units/day) and/or drug abuse (current or past)	yes <input type="checkbox"/>	no <input type="checkbox"/>
Inappropriate diet	yes <input type="checkbox"/>	no <input type="checkbox"/>
Cognitive impairment (Short Blessed Test > 9)	yes <input type="checkbox"/>	no <input type="checkbox"/>
ENVIRONMENTAL DOMAIN		
Institutionalization	yes <input type="checkbox"/>	no <input type="checkbox"/>
Difficult access to healthcare	yes <input type="checkbox"/>	no <input type="checkbox"/>
Presence of home architectural barriers	yes <input type="checkbox"/>	no <input type="checkbox"/>
Occupational exposure to toxins	yes <input type="checkbox"/>	no <input type="checkbox"/>
Air pollution	yes <input type="checkbox"/>	no <input type="checkbox"/>
CULTURAL DOMAIN		
Schooling < 8 years	yes <input type="checkbox"/>	no <input type="checkbox"/>
Insufficient access to information	yes <input type="checkbox"/>	no <input type="checkbox"/>
Lack of adherence to health screening programs	yes <input type="checkbox"/>	no <input type="checkbox"/>
Language barriers	yes <input type="checkbox"/>	no <input type="checkbox"/>
Perceived discrimination	yes <input type="checkbox"/>	no <input type="checkbox"/>

SMAC STUDY. CLINICAL COMPLEXITY OF A LONELY, UNWEALTHY, 85yr-OLD MAN ADMITTED FOR ACUTE HEART FAILURE



EVALUATED INDEXES


Author, year	Tool name	N. Items	Variables included	Strength and limitations
Linn et al., 1968	Cumulative illness rating scale (CIRS)	13, 5-point scale (0-4)	Cardiovascular-respiratory system, gastrointestinal system, genitourinary system, musculo-skeletal-integumentary system, neuropsychiatric system, general system	Biologic measure of aging; designated better than did chronological age the individual along his life span and with regard to his capacity for survival
Shah et al., 1989	Barthel Index	10, ADL functions rated on a scale with different scores	Personal hygiene, bathing self, feeding, toilet, stair climbing, dressing, bowel control, bladder control, ambulation, wheelchair*, chair/bed transfers	It is reliable and highly repeatable
Rolfson et al., 2006	Edmonton Frail Scale (EFS)	9, each rated on a 3-point scale (0-2)	Cognition, health status, functional dependence, social support, medication use, nutrition, mood, continence, functional performance	Easily available questionnaire to measure frailty in the elderly, both in a hospital and in an outpatient setting
Katzman et al., 1983	Short Blessed test (SBT)	6, each rated with different scores	Time orientation, ability to count backwards from 20 to 1, ability to say the months of the year in reverse order, and ability to repeat a memory phrase	Tool for detecting mild dementia and it is sensitive to subthreshold impairments; adversely affected by age and education
Connor et al., 2003	Connor-Davidson Resilience Scale (CD-RISC)	25, each rated on a 5-point scale (0-4)	Personal competence, high standards, and tenacity (a); trust in one's instincts, tolerance of negative affect, and strengthening effects of stress (b); positive acceptance of change and secure relationships (c); control (d); and spiritual influences (e)	The scale does not assess the resiliency process or provide information about the theory of resilience, it also has not been validated against an objective measure, or against biological measures of resilience
Morisky et al., 1986	MMAS-4 Morisky Medication Adherence Scale	4, each positive answer has a score of 0 and each negative of 1	Do you ever forget to take your medicine (a); Are you careless at times about taking your medicine? (b); Sometimes if you feel better when you take the medicine do you stop taking it?; Sometimes if you feel worse when you take the medicine do you stop taking it?	This questionnaire provides a measure of therapeutic adherence self-referred structured in four elements, it can also be completed independently by the user

CAPTURE-RECAPTURE TECHNIQUE

- if a patient was lost to follow-up, the capture-recapture technique was applied
- GP or other available phone numbers were the first means of recapture
- if the above did not work, we ascertained the vital status from the last known municipality of residence
- death certificates were obtained from the local mortality registry; the cause of death was classified according to the 9th International Classification of diseases

REPRODUCIBILITY IN THE ASSESSMENT OF CC

30 consecutive pts - 3 healthcare professionals



HOW DOES THE DECEMBER HOLIDAY PERIOD AFFECT CC?

106 cases (15 DEC-15 JAN) / 121 controls (16 JAN-16 FEB)

	Cases	Controls	<i>p</i>
Age (yrs)	79.4	74.3	0.014
CCI	17.7	15.2	0.001
Biological domain	7.8	7.1	NS
Socioeconomic domain	3.5	2.9	0.012
Behavioral domain	2.4	1.9	0.017
Environmental domain	1.3	1.0	NS
Cultural domain	2.7	2.2	NS
CIRS	3.7	3.5	NS
Length of stay (days)	15.5	11.0	0.001

CCI, age, & low income independently correlated with cases

ADMINISTRATIVE DATA FOR EXPLORING MULTIMORBIDITY

	Administrative data	Clinical data
Time required to gather data	Short, computer-aided	Long, time-consuming
Costs required to gather data	Low	High, a skilled research physician is needed
Amount of data	High	Usually low
Patient-reported outcomes	Not assessable	Easily assessable and comparable to physician-reported outcomes
Risk factors analysis	Can only be inferred or assumed from the records, no causal relation with disease	Can be directly assessed and patients can be stratified according to the risk factors
Retrospective vs prospective design	Retrospective may promptly analyse large amount of data, especially the costs of a specific intervention	Prospective collects clinically meaningful exposure data
Reproducibility	Potentially high if a standardised method is used (e.g., ICD codes); may be low due to misclassification and may vary in different healthcare systems	Potentially high when samples are age-, gender-, and ethnicity-matched; may be low due to other contextual variables; large sample size is needed
Clinical transferability	Poor	High
Policymaker transferability	High	Poor

HETEROGENEITY BETWEEN COMORBIDITY & MULTIMORBIDITY FRAMEWORKS

MCC recently reclassified into 2 ≠ MeSH

• Comorbidity additional conditions to a single disease under study

• Multimorbidity co-occurrence of multiple diseases in which no single one holds priority


<i>n. 1394</i>	<i>Comorbidity</i>	<i>Multimorbidity</i>	<i>p value</i>
Pts (%)	20.5	75.7	
CIRS (median)	2.97	4.09	<0.001
EFS >5 (%)	8.2	19.2	<0.001
Intake ≥5 medications (%)	50.9	78.7	<0.001
Median age (yrs)	71	82	<0.001
Age groups (%)			
18-64	36.7	11.0	
65-74	20.6	13.5	
75-84	28.3	37.7	
≥85	14.4	37.8	

HETEROGENEITY BETWEEN COMORBIDITY & MULTIMORBIDITY FRAMEWORKS (II)

Multivariable analysis for the clinical outcomes

	<u>Hospital mortality</u>	<u>30d Mortality</u>	<u>30d Readmission</u>
Comorbidity (OR)	0.60 ns	1.34 ns	0.97 ns
Multimorbidity (OR)	0.32 ns	0.73 ns	0.86 ns
Age ≥75 yrs (OR)	4.82 p=0.002	3.42 p<0.001	2.17 p=0.037

RESILIENCE, FRAILITY & AGEING IN HOSPITALISED PTS (n. 143)




at multivariable analysis, RES significantly related to FRA ($p=0.022$) in adults (<65 yrs) and to DEPENDENCY ($p=0.031$) in older patients (≥ 65 yrs)

RATE & RISK FACTORS FOR EARLY MORTALITY IN HOSPITALISED PTS (n. 1451)


	<i>In-hospital mortality (6.4%)</i>		<i>4-mo mortality (15.9%)</i>	
	<u>OR</u>	<u>p value</u>	<u>HR</u>	<u>p value</u>
Age	1.04	0.001	1.04	0.001
BMI <18.5	0.39	ns	2.13	0.001
Barthel index <60	2.60	0.001	1.65	0.002
CIRS >3	1.13	ns	0.80	ns
Drug intake >5	1.24	ns	1.25	ns
Length of stay	na	na	1.59	0.001

CO-MULTIMORBIDITY IN HOSPITALISED CIRRHOTIC PTS ACCORDING TO THE AETIOLOGY (n. 187)



at a multivariable analysis looking at factors affecting the risk of multimorbidity, admission related to cirrhosis was significantly and inversely correlated with this outcome

NEW SUBPROJECTS 2022-23



1

Determinants of multimorbidity in young adults (age 18-35) vs middle-aged adults (age 35-60)

2

Polypharmacy and drug overprescription at discharge in an internal medicine setting

3

Sociodemographic and clinical characteristics of oncological patients admitted to an internal medicine ward


4

Underlying factors of end-of-life in an internal medicine setting

5

Impact of physical exercise in frail individuals. A narrative review


MEDICARE ACUTE AND POST-ACUTE CARE PAYMENTS FOR 30-DAY EPISODES THAT BEGAN WITH HOSPITALIZATION




THE WORTHINESS OF INTERNAL MEDICINE. A HISTORICAL PERSPECTIVE

- **clinical reasoning >> technical skill**
- **flexibility from primary to tertiary care**
- **capacity to shift through vast changes of medicine**
- **ability to relate with other specialties**
- **best suited for the application of cost-effective strategies**

UNCOVERING DISEASE-DISEASE RELATIONSHIPS THROUGH THE "INTERACTOME"



DISTRIBUTION OF MULTIMORBIDITY IN RELATION TO AGE. A PRIMARY CARE DATABASE ON 1751841 SCOTTISH PTS



Barnett et al, *Lancet* 2012

? multimorbidity = complexity ?

FUTURE PERSPECTIVES ON CC

- **both biological and clinical complexity are on increase**
- **stakeholders should update training programmes and reimbursement systems**
- **reinforcement of general medical care is an absolute need to achieve coordinated care and reorganise in a more efficient way the bidirectional flows between territory and hospital**